Please login to the form below
Eleusis
This page shows the latest Eleusis news and features for those working in and with pharma, biotech and healthcare.
Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
Eleusis says the psychoactive properties of LSD stem from its action on the serotonin 5-HT. ... At the doses tested the psychoactive properties of LSD are below the level that is detectable by the recipient, says Eleusis.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
